[go: up one dir, main page]

WO2017215677A3 - Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie - Google Patents

Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie Download PDF

Info

Publication number
WO2017215677A3
WO2017215677A3 PCT/CN2017/097014 CN2017097014W WO2017215677A3 WO 2017215677 A3 WO2017215677 A3 WO 2017215677A3 CN 2017097014 W CN2017097014 W CN 2017097014W WO 2017215677 A3 WO2017215677 A3 WO 2017215677A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbocisteine
pharmaceutical composition
effects
treating leukemia
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/097014
Other languages
English (en)
Chinese (zh)
Other versions
WO2017215677A2 (fr
Inventor
崔坤峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017215677A2 publication Critical patent/WO2017215677A2/fr
Publication of WO2017215677A3 publication Critical patent/WO2017215677A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie. La composition pharmaceutique de carbocistéine selon la présente invention comprend de la carbocistéine et un composé naturel (I) ayant une nouvelle structure et isolé à partir de feuilles sèches de Pyrrosia lingua. Utilisés séparément, la carbocistéine et le produit naturel ont chacun un certain degré d'effet thérapeutique sur la leucémie, cet effet thérapeutique étant accru lorsqu'ils sont utilisés conjointement. Des médicaments pour le traitement de la leucémie peuvent être mis au point à partir de ceux-ci. Par rapport à l'état de la technique, la présente invention est plus favorable et présente des améliorations significatives.
PCT/CN2017/097014 2016-06-13 2017-08-11 Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie Ceased WO2017215677A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610412276.XA CN106074561A (zh) 2016-06-13 2016-06-13 羧甲司坦的药物组合物及其对白血病的治疗作用
CN201610412276.X 2016-06-13

Publications (2)

Publication Number Publication Date
WO2017215677A2 WO2017215677A2 (fr) 2017-12-21
WO2017215677A3 true WO2017215677A3 (fr) 2018-02-15

Family

ID=57846453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/097014 Ceased WO2017215677A2 (fr) 2016-06-13 2017-08-11 Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie

Country Status (2)

Country Link
CN (1) CN106074561A (fr)
WO (1) WO2017215677A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105837422A (zh) * 2016-04-20 2016-08-10 宋晓梅 一种盐酸丁丙诺啡的药物组合物及其在生物医药中的应用
CN106074561A (zh) * 2016-06-13 2016-11-09 崔坤峰 羧甲司坦的药物组合物及其对白血病的治疗作用
CN106117166A (zh) * 2016-06-23 2016-11-16 崔坤峰 氨力农的药物组合物及其在高血压治疗中的应用
CN106045835A (zh) * 2016-06-23 2016-10-26 崔坤峰 盐酸苄丝肼的药物组合物及其降血糖的医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102805746A (zh) * 2011-06-02 2012-12-05 湖南九典制药有限公司 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用
CN106074561A (zh) * 2016-06-13 2016-11-09 崔坤峰 羧甲司坦的药物组合物及其对白血病的治疗作用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100584362C (zh) * 2007-08-02 2010-01-27 徐平 一种治疗白血病的中药

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102805746A (zh) * 2011-06-02 2012-12-05 湖南九典制药有限公司 一种作用于呼吸系统疾病的复方化学药及其制备工艺与应用
CN106074561A (zh) * 2016-06-13 2016-11-09 崔坤峰 羧甲司坦的药物组合物及其对白血病的治疗作用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG YUANCHAO ET AL.: "Study on chemical constituents and pharmacological activities of Friedelane Triterpenes in Celastraceae", RESEARCH AND PRACTICE ON CHINESE MEDICINES, 31 December 2015 (2015-12-31), pages 73 - 79, ISSN: 1673-6427 *

Also Published As

Publication number Publication date
WO2017215677A2 (fr) 2017-12-21
CN106074561A (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
ZA202103074B (en) Formulation based on medicinal plant, or part or extract thereof, use of the formulation and product including said formulation
SI3433256T1 (sl) Derivat 6,7,8,9-tetrahidro-3H-pirazolo(4,3-f)izokinolina uporabni v zdravljenju raka
EP4541361A3 (fr) Traitement du cancer par manipulation de la microflore commensale
WO2018013609A8 (fr) Nanoparticules synthétiques de mélanine et leurs utilisations
WO2018067512A8 (fr) Composés spirocycliques
EP3398948A3 (fr) Dérivés de ptéridine 2,4,6,7-tétrasubstituée et leurs procédés de synthèse et d'utilisation
WO2018023072A3 (fr) Composés et compositions, et utilisations associées
WO2017136450A3 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
EP4520828A3 (fr) Compositions et procédés pour le traitement de l'angiogenèse aberrante
HK1251482A1 (zh) 用於治疗补体介导的疾病的组合物和方法
WO2017215677A3 (fr) Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie
EP4327887A3 (fr) Combinaisons et formulations à dose fixe comprenant etc1002 et une ou plusieurs statines et procédés de traitement ou de réduction du risque de maladie cardiovasculaire
WO2017079403A3 (fr) Nanoparticules polymères
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
WO2016115054A3 (fr) Modulateurs de canaux calciques ca2+ activés par la libération de calcium ca2+ (crac) et leurs utilisations pharmaceutiques
WO2017220042A3 (fr) Composition pharmaceutique d'amrinone et son application dans le traitement de l'hypertension
FR3044226B1 (fr) Extrait alcoolique de parties aeriennes de solidago virgaurea subsp. alpestris, son procede d'obtention, et composition cosmetique ou dermatologique le contenant
WO2017215678A3 (fr) Composition pharmaceutique de céfaclor et ses effets protecteurs contre les lésions pulmonaires aiguës
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
EP3554496A4 (fr) Procédés et compositions de traitement de la maladie de parkinson
PH12016501205B1 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
WO2016081671A8 (fr) Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
EP3441076A4 (fr) Produit pharmaceutique destiné au traitement d'une tumeur et d'un défaut immunitaire combiné, préparation et application de ce dernier
EP3634979A4 (fr) Compositions et procédés de traitement de la maladie d'alzheimer
HUE057090T2 (hu) BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17812788

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17812788

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04/07/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17812788

Country of ref document: EP

Kind code of ref document: A2